manganese superoxide dismutase Inhibitors
2 drugsAbout manganese superoxide dismutase
Manganese superoxide dismutase (MnSOD) neutralizes superoxide radicals within mitochondria, converting them to hydrogen peroxide and oxygen. This enzyme plays a vital role in cellular antioxidant defense, managing oxidative stress.
MnSOD's role in managing oxidative stress makes it a potential drug target, though there is currently no genetic evidence directly linking it to specific diseases.
Two FDA-approved small molecule drugs, MULTRYS and TRALEMENT, target MnSOD, both approved in 2020 by AM REGENT for therapeutic areas classified as 'other'.
Top manganese superoxide dismutase Drugs
AM REGENT is the only company with approved drugs targeting MnSOD.
Low competition may present an opportunity for new market entrants.
manganese superoxide dismutase Drug Modality Landscape
Modalities
Routes of Administration
manganese superoxide dismutase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like biologics could provide differentiation.
manganese superoxide dismutase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on manganese superoxide dismutase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
manganese superoxide dismutase Drug Approval Timeline (2020 - 2020)
The first and most recent drug approvals for MnSOD were in 2020.
Recent approvals suggest renewed interest, but saturation may soon occur.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on manganese superoxide dismutase. A trial counts if an approved drug acting on manganese superoxide dismutase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.